Inhibitor of cyclin-dependent kinases (CDKs), with selectivity for CDK1/cyclin B (IC50=55nM), CDK2/cyclin A (IC50=35nM), CDK2/cyclin E (IC50=150nM), CDK4/cyclin D1 (IC50=300nM), CDK5/p35 (IC50=65nM) and GSK-3β (IC50=280nM).
Product Details
| Alternative Name: | E226, Indirubin-5-sulphonate . Na |
| |
| Formula: | C16H9N2O5S . Na |
| |
| MW: | 341.3 . 23.0 |
| |
| Purity: | ≥95% (1H-NMR) |
| |
| Identity: | Determined by 1H-NMR. |
| |
| Appearance: | Black powder. |
| |
| Solubility: | Soluble in DMSO or water. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?: S. Leclerc, et al.; J. Biol. Chem.
276, 251 (2001),
Abstract;
Full Text
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells: D. Marko, et al.; Br. J. Cancer
84, 283 (2001),
Abstract;
Inhibitor binding to active and inactive cdk2. the crystal structure of cdk2-cyclin a/indirubin-5-sulphonate: T.G. Davies, et al.; Structure (Camb)
9, 389 (2001),
Abstract;
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases: R. Hoessel, et al.; Nat. Cell. Biol.
1, 60 (1999),
Abstract;
Related Products
